A5005215481- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Heart rate and cardiovascular health
- Receptor Mechanisms and Signaling
- Heart Rate Variability and Autonomic Control
- Cardiac Fibrosis and Remodeling
- Peptidase Inhibition and Analysis
- Cardiac Ischemia and Reperfusion
- Cardiac electrophysiology and arrhythmias
- Phosphodiesterase function and regulation
- Cardiac pacing and defibrillation studies
- Neuroscience and Neural Engineering
University of Colorado Anschutz Medical Campus
2022-2025
Heart rate (HR) affects heart failure outcomes, via uncertain mechanisms that may include left ventricular remodeling. However, in human myocardium, HR change has not been associated with a particular remodeling molecular phenotype. Patients nonischemic dilated cardiomyopathy (N=22) sinus rhythm and refractory to β-blockade for both lowering reverse were randomized 2:1 double-blind the HCN4 (hyperpolarization-activated cyclic nucleotide-gated potassium channel 4) inhibitor ivabradine or...
Organ fibrosis due to excessive production of extracellular matrix by resident fibroblasts is estimated contribute >45% deaths in the Western world, including those cardiovascular diseases such as heart failure. Here, we screened for small molecule inhibitors with a common ability suppress activation across organ systems.High-content imaging cultured cardiac, pulmonary, and renal was used identify nontoxic compounds that blocked induction markers response profibrotic stimulus, transforming...
Increasing SERCA2 (sarco[endo]-plasmic reticulum Ca2+ ATPase 2) activity is suggested to be beneficial in chronic heart failure, but no selective SERCA2-activating drugs are available. PDE3A (phosphodiesterase 3A) proposed present the interactome and limit activity. Disruption of from might thus a strategy develop activators.Confocal microscopy, 2-color direct stochastic optical reconstruction proximity ligation assays, immunoprecipitations, peptide arrays, surface plasmon resonance were...
In a 2-center trial ( P ulse R eduction o n Be ta-Blocker and I vabradine T herapy (PROBE-IT)) we tested the hypothesis that failure to adequately reduce heart rate (HR) contributes non-response beta-blockers. Twenty-two dilated cardiomyopathy patients (DCM) with sinus rhythm (SR) ≥70 bpm without reverse remodeling after target doses of beta-blockers were randomized 2:1 5±2.5 mg b.i.d ivabradine (IVB) or matching placebo, treated for 24 weeks continuation Echocardiograms LVEF measurements...
Introduction: Children with heart failure (HF) due to dilated cardiomyopathy (DCM) or single ventricle congenital disease (SV) ultimately require transplantation the lack of effective medical therapies. Inhibition PDE1 (PDE1i) is currently being investigated in adult HF, however it unclear if PDE1i use should be extrapolated pediatric HF. Objective: To evaluate acute effect on loaded myocardial contractility DCM and SV trabeculae. Methods: Hearts were obtained from (N=25) (N=27) children who...